<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375671</url>
  </required_header>
  <id_info>
    <org_study_id>H17-00571</org_study_id>
    <nct_id>NCT03375671</nct_id>
  </id_info>
  <brief_title>Rapid Agitation Control With Ketamine in the Emergency Department</brief_title>
  <acronym>RACKED</acronym>
  <official_title>Rapid Agitation Control With Ketamine in the Emergency Department (RACKED): a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Barbic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St Paul's Emergency Department Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Health Evaluation and Outcome Sciences (CHÉOS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare intramuscular (IM) ketamine to a combination of IM midazolam and haloperidol with
      regards to the time required for adequate behavioral control, in minutes, in patients
      presenting to the emergency department with psychomotor agitation and violent behavior.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from first IM medication administration to adequate sedation which is defined as RASS less than or equal to -1.</measure>
    <time_frame>1 day</time_frame>
    <description>Measured using Richmond Agitation Sedation Scale (RASS) in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage participants with adverse events in each arm</measure>
    <time_frame>up to 4 days</time_frame>
    <description>measured by AE collection in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in each arm requiring rescue medications between 5 and 30 minutes (at 5 minutes interval) after study medication(s) administration by count.</measure>
    <time_frame>1 day</time_frame>
    <description>measured by rescue medication administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in each arm experiencing sedation outcomes as defined by the TROOPS criteria</measure>
    <time_frame>1 day</time_frame>
    <description>measured using Tracking and Reporting Outcomes of Procedural Sedation (TROOPS) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with neuroleptic malignant syndrome events within 24 hours of enrollment of each arm.</measure>
    <time_frame>1 day</time_frame>
    <description>measured by occurrence of neuroleptic malignant syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing pre-hospital use of force by police in this participant population, by number and type of restraint.</measure>
    <time_frame>1 day</time_frame>
    <description>measured by police account at study enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant experience survey outcomes.</measure>
    <time_frame>1 day</time_frame>
    <description>measured using Participant Experience Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Nurse Experience survey outcomes.</measure>
    <time_frame>1 day</time_frame>
    <description>measured using Study Nurse Experience Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Blinding survey outcomes</measure>
    <time_frame>1 day</time_frame>
    <description>measured using Effectiveness of Study Drug Blinding Survey</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Violent Aggressive Behavior</condition>
  <condition>Ketamine</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam + haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketalar</intervention_name>
    <description>single administration of 5 mg/kg, IM</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <description>single administration of 5 mg, IM</description>
    <arm_group_label>Midazolam + haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>single administration of 5 mg, IM</description>
    <arm_group_label>Midazolam + haloperidol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19 - 60 years inclusively;

          2. Patients presenting to the emergency department with psychomotor agitation or violent
             behaviour (RASS score &gt; +3).

        Exclusion Criteria:

          1. Less than 19 years of age;

          2. Greater than 60 years of age;

          3. Previous participation in this study;

          4. Women suspected or known to be pregnant or breastfeeding;

          5. Previous known hypersensitivity, intolerance or allergy to ketamine, midazolam or
             haloperidol or their components.

          6. Subjects who are in comatose states or have CNS depression due to alcohol or are
             taking other depressant drugs.

          7. Subjects with severe depressive states, spastic diseases and in Parkinson's syndrome,
             except in the case of dyskinesias due to levodopa treatment.

          8. Senile patients with pre-existing Parkinson-like symptoms.

          9. Subjects with a history of cerebrovascular accident

         10. Subjects in whom a significant elevation of blood pressure would constitute a serious
             hazard, such as patients with significant hypertension

         11. Subjects with severe cardiac decompensation

         12. Subjects who intend to have surgery of the pharynx, larynx, or bronchial tree unless
             adequate muscle relaxants are used

         13. Subjects with acute pulmonary insufficiency

         14. Subjects with severe chronic obstructive pulmonary disease

         15. Subjects with acute narrow angle glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Barbic, MD MSc FRCPC,</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Love</last_name>
    <phone>604-682-2344</phone>
    <phone_ext>64242</phone_ext>
    <email>llove@cheos.ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Barbic, MD MSc FRCPC</last_name>
    <phone>604-806-8480</phone>
    <email>david.barbic@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Paul's Hospital Emergency Department</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Barbic</last_name>
      <phone>604-806-8480</phone>
      <email>david.barbic@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>David Barbic, MD MSc FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>David Barbic</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>aggressive behaviour</keyword>
  <keyword>midazolam</keyword>
  <keyword>haloperidol</keyword>
  <keyword>emergency department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

